Abdul Jaber Tayem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdul Jaber Tayem has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Abdulrahman Khaldoon Hamid
College of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication - Ahmad Bani-Jaber
Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, The University of Jordan, Amman, Jordan
1 shared publication - Ahmad M. Altantawi
University of Jordan, School of Medicine
1 shared publication - Ahmed Sermed Al Sakini
College of Medicine University of Baghdad Baghdad Iraq
1 shared publication Angel Liu
Visual Outcomes Lab, Department of Neurology Cedars Sinai Medical Center Los Angeles California USA
1 shared publicationArzu C. Has Silemek
Neuroimaging Program Cedars Sinai Medical Center Los Angeles California USA
1 shared publication
Latest Publications
- Open Access
- 17 March 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (9) , 1831-1841
Paramagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis
Objectives: Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss. We investigated associations between rTSD, paramagnetic rim lesions (PRL), and longitudinal visual disability in people with MS (pwMS) using a novel optical coherence tomography (OCT) based biomarker of rTSD. Methods: PwMS, non‐MS neurological disease controls, and healthy controls underwent OCT, multiparametric brain MRI, and clinical assessments. A quantitative rTSD index was developed to capture hemispheric GCIPL asymmetry, with absolute values reflecting rTSD severity. Generalized linear models were used to investigate MRI and clinical predictors of rTSD. Longitudinal changes in rTSD were evaluated using mixed‐effects linear regression models. Results: A total of 170 pwMS and 49 controls were included. PwMS had higher rTSD than healthy ( p = 0.006) and non‐MS controls ( p = 0.009). African American race ( p = 0.02) and longer disease duration ( p = 0.005) were associated with higher baseline rTSD. PRL in the optic radiations (OR) was linked to a 4.5‐fold increase in rTSD ( p = 0.037; n = 37) and −1.18 dB reduction in hemifield sensitivity ( p = 0.018). Longitudinally, each unit/year progression in rTSD was associated with a −0.07 dB/year decline in hemifield sensitivity ( p = 0.005) and a 10.8‐fold increase in the odds of expanded disability status scale score progression ( p = 0.022). Higher body mass index was associated with faster rTSD progression longitudinally ( p = 0.02). Interpretation: PRL in the OR, African American race, disease duration, and higher BMI are associated with rTSD in pwMS. Longitudinal increase in rTSD is associated with worsening visual loss and clinical disability progression in MS. Trial Registration: ClinicalTrials.gov identifier: NCT05204459
- 17 March 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (9) , 1831-1841
Open AccessParamagnetic Rim Lesions Are Associated With Trans‐Synaptic Degeneration of the Visual Pathway in Multiple Sclerosis
Objectives: Retrograde trans‐synaptic degeneration (rTSD) from posterior visual pathway lesions in multiple sclerosis (MS) is characterized by hemi‐macular ganglion cell‐inner plexiform layer (GCIPL) thinning and contralateral visual field loss. We investigated associations between rTSD, paramagnetic rim lesions (PRL), and longitudinal visual disability in people with MS (pwMS) using a novel optical coherence tomography (OCT) based biomarker of rTSD. Methods: PwMS, non‐MS neurological disease controls, and healthy controls underwent OCT, multiparametric brain MRI, and clinical assessments. A quantitative rTSD index was developed to capture hemispheric GCIPL asymmetry, with absolute values reflecting rTSD severity. Generalized linear models were used to investigate MRI and clinical predictors of rTSD. Longitudinal changes in rTSD were evaluated using mixed‐effects linear regression models. Results: A total of 170 pwMS and 49 controls were included. PwMS had higher rTSD than healthy ( p = 0.006) and non‐MS controls ( p = 0.009). African American race ( p = 0.02) and longer disease duration ( p = 0.005) were associated with higher baseline rTSD. PRL in the optic radiations (OR) was linked to a 4.5‐fold increase in rTSD ( p = 0.037; n = 37) and −1.18 dB reduction in hemifield sensitivity ( p = 0.018). Longitudinally, each unit/year progression in rTSD was associated with a −0.07 dB/year decline in hemifield sensitivity ( p = 0.005) and a 10.8‐fold increase in the odds of expanded disability status scale score progression ( p = 0.022). Higher body mass index was associated with faster rTSD progression longitudinally ( p = 0.02). Interpretation: PRL in the OR, African American race, disease duration, and higher BMI are associated with rTSD in pwMS. Longitudinal increase in rTSD is associated with worsening visual loss and clinical disability progression in MS. Trial Registration: ClinicalTrials.gov identifier: NCT05204459
- Open Access
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1214-1224
Increased vulnerability to low-density lipoprotein cholesterol in apolipoprotein E4-positive females: Longitudinal effects on neurodegeneration and cognition
Background: Alzheimer's disease (AD) is the most common form of dementia, marked by progressive cognitive decline. Low-density lipoprotein cholesterol (LDL-C) has been implicated in AD pathology, but findings remain inconsistent. Apolipoprotein E4 (APOE4) status and sex may contribute to this variability. Objective: To examine how LDL-C association with neurodegeneration in AD patients, differ according to APOE4 status and gender. Methods: We stratified 106 AD patients by APOE4 status and sex into four subgroups: male APOE4+, female APOE4+, male APOE4−, and female APOE4−. Longitudinal cortical thickness changes were assessed using magnetic resonance imaging (MRI). We examined the association between LDL-C levels and cortical thinning within each subgroup. Results: In APOE4-positive females, higher LDL-C levels were significantly associated with accelerated cortical thinning in several regions, including the parahippocampal (β = −0.0075, p = 0.017), medial orbitofrontal (β = −0.0025, p = 0.028), fusiform (β = −0.0047, p = 0.034), posterior cingulate (β = −0.0097, p = 0.006), and inferior temporal cortices (β = −0.0085, p = 0.019). This subgroup also showed a significant association between LDL-C and MMSE decline (β = −1.409, p = 0.014) as well as longitudinal increases in cerebrospinal fluid phosphorylated tau181 (β = 0.014, p = 0.039). These effects were not observed in other subgroups. Conclusions: Elevated LDL-C is associated with increased neurodegeneration and cognitive decline in female AD patients carrying the APOE4 allele. These exploratory findings highlight a subgroup-specific vulnerability to lipid-related neurodegeneration in AD and underscore the importance of considering both sex and genetic background in future studies.
- 13 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (3) , 1214-1224
Open AccessIncreased vulnerability to low-density lipoprotein cholesterol in apolipoprotein E4-positive females: Longitudinal effects on neurodegeneration and cognition
Background: Alzheimer's disease (AD) is the most common form of dementia, marked by progressive cognitive decline. Low-density lipoprotein cholesterol (LDL-C) has been implicated in AD pathology, but findings remain inconsistent. Apolipoprotein E4 (APOE4) status and sex may contribute to this variability. Objective: To examine how LDL-C association with neurodegeneration in AD patients, differ according to APOE4 status and gender. Methods: We stratified 106 AD patients by APOE4 status and sex into four subgroups: male APOE4+, female APOE4+, male APOE4−, and female APOE4−. Longitudinal cortical thickness changes were assessed using magnetic resonance imaging (MRI). We examined the association between LDL-C levels and cortical thinning within each subgroup. Results: In APOE4-positive females, higher LDL-C levels were significantly associated with accelerated cortical thinning in several regions, including the parahippocampal (β = −0.0075, p = 0.017), medial orbitofrontal (β = −0.0025, p = 0.028), fusiform (β = −0.0047, p = 0.034), posterior cingulate (β = −0.0097, p = 0.006), and inferior temporal cortices (β = −0.0085, p = 0.019). This subgroup also showed a significant association between LDL-C and MMSE decline (β = −1.409, p = 0.014) as well as longitudinal increases in cerebrospinal fluid phosphorylated tau181 (β = 0.014, p = 0.039). These effects were not observed in other subgroups. Conclusions: Elevated LDL-C is associated with increased neurodegeneration and cognitive decline in female AD patients carrying the APOE4 allele. These exploratory findings highlight a subgroup-specific vulnerability to lipid-related neurodegeneration in AD and underscore the importance of considering both sex and genetic background in future studies.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 18
Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis
Background: Heart failure (HF) is a highly prevalent disease, among the primary factors contributing to morbidity and death. One of its types is heart failure with preserved ejection fraction (HFpEF) comprising 40%–50% of newly diagnosed HF cases. Despite the high prevalence of HFpEF, there is still a lack of knowledge regarding the best drugs and treatment approaches to be used. However, the sodium-glucose co-transporter 2 (SGLT2) inhibitors could be a promising treatment. Objectives: To examine SGLT2 inhibitors’ effect on hospitalization, cardiovascular death, and estimated glomerular filtration rate (eGFR) in HFpEF patients. Search methods: We conducted searches for randomized controlled trials (RCTs) in PubMed, Embase, Scopus, and Web of Science up to July 2024. Selection criteria: We chose RCTs that examined the effects of SGLT2 inhibitors and placebo in individuals with higher than 40% ejection fraction (HFpEF). Data collection and analysis: The methodology for the systematic review and meta-analysis was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Main results: We included 8 studies with 16,509 participants. Drugs examined in our paper included empagliflozin, dapagliflozin, sotogliflozin, and ertugliflozin. Various outcomes were analyzed in different papers. However, different SGLT2 inhibitors lead to a decreased risk of cardiovascular hospitalization and kidney injury. Our meta-analysis showed a decreased risk of cardiovascular hospitalization but not death due to cardiovascular causes or other causes. These results were regardless of baseline status of eGFR, systolic blood pressure, atrial fibrillation or flutter, diabetes mellitus, sex, body mass index, and nt-proBNP. The included studies were of moderate to high quality. Conclusion: For individuals with HFpEF, SGLT2 inhibitors have been proven to be a safe and effective medication. However, more studies are needed for longer durations, reporting adverse events, effects on exercise tolerance, and other secondary outcomes.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 18
Open AccessEmpagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis
Background: Heart failure (HF) is a highly prevalent disease, among the primary factors contributing to morbidity and death. One of its types is heart failure with preserved ejection fraction (HFpEF) comprising 40%–50% of newly diagnosed HF cases. Despite the high prevalence of HFpEF, there is still a lack of knowledge regarding the best drugs and treatment approaches to be used. However, the sodium-glucose co-transporter 2 (SGLT2) inhibitors could be a promising treatment. Objectives: To examine SGLT2 inhibitors’ effect on hospitalization, cardiovascular death, and estimated glomerular filtration rate (eGFR) in HFpEF patients. Search methods: We conducted searches for randomized controlled trials (RCTs) in PubMed, Embase, Scopus, and Web of Science up to July 2024. Selection criteria: We chose RCTs that examined the effects of SGLT2 inhibitors and placebo in individuals with higher than 40% ejection fraction (HFpEF). Data collection and analysis: The methodology for the systematic review and meta-analysis was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Main results: We included 8 studies with 16,509 participants. Drugs examined in our paper included empagliflozin, dapagliflozin, sotogliflozin, and ertugliflozin. Various outcomes were analyzed in different papers. However, different SGLT2 inhibitors lead to a decreased risk of cardiovascular hospitalization and kidney injury. Our meta-analysis showed a decreased risk of cardiovascular hospitalization but not death due to cardiovascular causes or other causes. These results were regardless of baseline status of eGFR, systolic blood pressure, atrial fibrillation or flutter, diabetes mellitus, sex, body mass index, and nt-proBNP. The included studies were of moderate to high quality. Conclusion: For individuals with HFpEF, SGLT2 inhibitors have been proven to be a safe and effective medication. However, more studies are needed for longer durations, reporting adverse events, effects on exercise tolerance, and other secondary outcomes.